Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Collaboration and Stock Purchase Agreements and Asset Acquisitions (Narrative) (Details)

Collaboration and Stock Purchase Agreements and Asset Acquisitions (Narrative) (Details) $ / shares in Units, $ in Thousands, shares in Millions						1 Months Ended		12 Months Ended
	Oct. 11, 2022 USD ($)	Oct. 06, 2021	Oct. 05, 2021 USD ($)	Feb. 24, 2021 USD ($) Milestone	Nov. 12, 2018	Sep. 30, 2021 USD ($)	Feb. 28, 2019 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaboration revenue								$ 1,882	$ 5,389
Cyprium [Member] \| Sentynl Therapeutics, Inc [Member]
Upfront fees payment				$ 8,000
Payments of milestones				$ 12,000
Percentage of ownership over any FDA priority review voucher				100.00%
Number of development milestones \| Milestone				2
Collaboration revenue								$ 1,900	$ 5,400
Avenue Therapeutics, Inc [Member] \| InvaGen [Member]
Percentage of shares repurchased	100.00%
Purchase price of shares repurchased	$ 3,000
Percentage of contingent fee payable	7.50%
Contingent fee payable from proceeds of future financing	$ 4,000
Caelum \| AstraZeneca [Member]
Deconsolidation of consolidated partner company, percentage deconsolidated		100.00%	100.00%
Percentage of proceeds from option exercise			42.40%			42.40%
Option exercise price			$ 150,000			$ 150,000
Proceeds from option exercise			$ 56,900			$ 56,900
Percentage of escrow holdback			10.00%
Revenue from collaboration agreement			$ 148,600
Maximum \| Caelum \| AstraZeneca [Member]
Revenue from collaboration agreement			$ 350,000
SPMA [Member] \| Avenue Therapeutics, Inc [Member] \| InvaGen [Member]
Sale of stock, ownership percentage after the transaction					33.30%
FDA approval of the NDA [Member] \| Cyprium [Member] \| Sentynl Therapeutics, Inc [Member]
Payments of milestones				$ 9,000
Strategic Transaction, First Stage [Member] \| SPMA [Member] \| Avenue Therapeutics, Inc [Member] \| InvaGen [Member]
Sale of stock, number of shares issued \| shares							5.8
Stock offering, price per share \| $ / shares							$ 6.00
Sale of Stock, Consideration Received on Transaction							$ 35,000
Sale of stock, ownership percentage after the transaction							33.30%
Completion of Clinical Development Milestones [Member] \| Cyprium [Member] \| Sentynl Therapeutics, Inc [Member]
Payments of milestones				$ 3,000